Buys | $0 | 0 | 0 |
Sells | $1,266,609 | 19 | 100 |
Yaffe Kristine | director | 0 | $0 | 1 | $25,309 | $-25,309 |
Hammond Paula | director | 0 | $0 | 1 | $53,179 | $-53,179 |
GRASSO MARC | Chief Financial Officer | 0 | $0 | 4 | $136,917 | $-136,917 |
Romano Gary | Chief Medical Officer | 0 | $0 | 4 | $141,413 | $-141,413 |
SCHELLER RICHARD H | director | 0 | $0 | 1 | $228,388 | $-228,388 |
Kenkare-Mitra Sara | President and Head of R&D | 0 | $0 | 4 | $240,780 | $-240,780 |
Rosenthal Arnon | Chief Executive Officer | 0 | $0 | 4 | $440,623 | $-440,623 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that …
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.27M worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $19.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
2025-03-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 40,330 0.0419% | $1.47 | $59,176 | +2.11% | |
2025-03-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 29,073 0.0302% | $1.47 | $42,662 | +2.11% | |
2025-03-03 | Sale | Romano Gary | Chief Medical Officer | 16,306 0.0169% | $1.47 | $23,927 | +2.11% | |
2025-03-03 | Sale | GRASSO MARC | Chief Financial Officer | 18,091 0.0188% | $1.47 | $26,547 | +2.11% | |
2024-12-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 52,172 0.0534% | $2.52 | $131,442 | -29.08% | |
2024-12-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 26,500 0.0271% | $2.52 | $66,764 | -29.08% | |
2024-12-02 | Sale | Romano Gary | Chief Medical Officer | 14,892 0.0152% | $2.52 | $37,519 | -29.08% | |
2024-12-02 | Sale | GRASSO MARC | Chief Financial Officer | 16,489 0.0169% | $2.52 | $41,542 | -29.08% | |
2024-09-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 26,499 0.0282% | $4.88 | $129,387 | -53.28% | |
2024-09-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,926 0.0148% | $4.88 | $67,981 | -53.28% | |
2024-09-03 | Sale | Romano Gary | Chief Medical Officer | 8,478 0.009% | $4.88 | $41,385 | -53.28% | |
2024-09-03 | Sale | GRASSO MARC | Chief Financial Officer | 7,297 0.0078% | $4.88 | $35,620 | -53.28% | |
2024-08-22 | Sale | SCHELLER RICHARD H | director | 44,250 0.0463% | $5.16 | $228,388 | -50.30% | |
2024-08-12 | Sale | Yaffe Kristine | director | 5,000 0.0051% | $5.06 | $25,309 | -28.77% | |
2024-08-12 | Sale | Hammond Paula | director | 10,500 0.0108% | $5.06 | $53,179 | -28.77% | |
2024-06-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 25,135 0.0249% | $4.80 | $120,618 | -9.74% | |
2024-06-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,206 0.0131% | $4.80 | $63,373 | -9.74% | |
2024-06-03 | Sale | Romano Gary | Chief Medical Officer | 8,040 0.008% | $4.80 | $38,582 | -9.74% | |
2024-06-03 | Sale | GRASSO MARC | Chief Financial Officer | 6,920 0.0068% | $4.80 | $33,208 | -9.74% | |
2024-03-04 | Sale | Rosenthal Arnon | Chief Executive Officer | 18,837 0.0195% | $6.92 | $130,386 | -29.30% |
GORDON CARL L | 10434976 10.5312% | $15.13M | 1 | 0 | +10.01% | |
ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.9243% | $2.76M | 1 | 17 | +10.01% |
Wehner David M. | director | 44621 0.045% | $64,700.45 | 1 | 0 | <0.0001% |
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$2,924,567 | 72 | -4.87% | $157.74M | |
$909,129 | 37 | 42.19% | $127.55M | |
$35,190,048 | 32 | 37.32% | $150.49M |
Increased Positions | 79 | +42.93% | 20M | +27.35% |
Decreased Positions | 75 | -40.76% | 19M | -26.21% |
New Positions | 31 | New | 17M | New |
Sold Out Positions | 39 | Sold Out | 11M | Sold Out |
Total Postitions | 188 | +2.17% | 73M | +1.14% |
Fmr Llc | $21,300.00 | 14.84% | 14.69M | +94,851 | +0.65% | 2024-12-31 |
Ra Capital Management, L.P. | $14,058.00 | 9.79% | 9.7M | +10M | New | 2024-12-31 |
Blackrock, Inc. | $13,248.00 | 9.23% | 9.14M | -215,297 | -2.3% | 2024-12-31 |
Vanguard Group Inc | $8,144.00 | 5.67% | 5.62M | +160,652 | +2.94% | 2024-12-31 |
Merck & Co., Inc. | $5,141.00 | 3.58% | 3.55M | +4M | New | 2024-12-31 |
Geode Capital Management, Llc | $2,776.00 | 1.93% | 1.91M | +10,308 | +0.54% | 2024-12-31 |
State Street Corp | $2,681.00 | 1.87% | 1.85M | -767,514 | -29.33% | 2024-12-31 |
Jpmorgan Chase & Co | $2,382.00 | 1.66% | 1.64M | -1M | -39.81% | 2024-12-31 |
Euclidean Capital Llc | $1,896.00 | 1.32% | 1.31M | 0 | 0% | 2024-12-31 |
Deutsche Bank Ag | $1,604.00 | 1.12% | 1.11M | -48,050 | -4.16% | 2024-12-31 |